
Today on Drug Discovery & Development
How CTF is trying to rescue pharma’s shelved rare disease drugs
Right now, more than 5,000 potential rare disease treatments are sitting on drug company shelves, according to Children’s Tumor Foundation (CTF) CEO Annette Bakker. That includes drug candidates that companies have stopped actively developing, often after substantial preclinical, toxicology or early clinical work. Nonprofit organizations can help close the gap. One example is the Children’s…CEPI fast-tracks ebola vaccine candidates from IAVI, Moderna and Oxford
The Coalition for Epidemic Preparedness Innovations (CEPI) announced the fast-tracking of three investigational vaccines to combat the Bundibugyo ebolavirus (BDBV) epidemic in the Democratic Republic of the Congo (DRC) and Uganda. CEPI selected IAVI, Moderna and the University of Oxford’s vaccine candidates based on a global review and consultations with the WHO, Africa CDC and…Drug Discovery and Development See More >

Top pharma companies set sustainability goals, but emissions are still increasing
The health care industry contributes an estimated 4.4% of total global emissions annually. Approximately 71% of this comes from the health care supply chain, which includes the pharmaceutical and biotechnology sectors. Medicines contribute approximately 20% to 55% of health care’s total carbon footprint. This comes from corporate emissions, API production and manufacturing. Pharmaceutical manufacturing is…

SLAS 2026: Orchestration patforms, API-first instruments and the rise of semiautonomous labs

How digital tools and AI are accelerating drug discovery

Pharma 2035 Playbook: Speed, focus and conviction in an uncertain world

STEERLife’s FragMelt platform manufactures drugs with heat sensitive active ingredient
Sponsored Content See More >
Genomics/Proteomics See More >

Beyond the silver bullet: Why precision medicine is the next frontier for the $1 trillion obesity market
“I remember when we decided the internet was going to cure everything, and it didn’t…it came with a certain set of problems,” said Mark Bagnall, CEO of Phenomix Sciences. GLP-1s are having a similar moment, he says. GLP-1s have been transformative for many; by 2025, more than 30 million Americans were taking them for weight…

Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification

Spatial biology: Transforming our understanding of cellular environments

Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials

Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
Infectious Disease See More >

FDA refuses to review Moderna’s mRNA flu vaccine
Moderna received a refusal-to-file (RTF) letter from the FDA’s Center for Biologics Evaluation and Research (CBER) for its investigational mRNA vaccine for influenza, the company said Tuesday. The letter is inconsistent with the feedback received at pre-Phase 3 and pre-submission consultations, Moderna said. The company has requested a meeting with the FDA. The vaccine, mRNA-1010,…
Oncology See More >

Beyond PD-1: The drugs reshaping cancer treatment at ASCO 2026
Biotech is heating up again. The SPDR S&P Biotech ETF (XBI) has gained roughly 69% over the past year. Global life sciences M&A hit $240 billion in 2025, an 81% jump from the prior year, with EY reporting a record $2.1 trillion in deal capacity. Goldman Sachs expects broader M&A volume to rise sharply in…

BioNTech made €19B in 2021. This quarter: €118M. Now it’s cutting 1,860 jobs and betting €16.8B in cash on returning to its oncology roots.

UCLA researchers advance EGFR-targeted drug for glioblastoma into clinical testing

Small study suggests probiotic yogurt strain may boost immunotherapy response in lung cancer





























